References
- PHACResponding to the Challenge of Diabetes in Canada – National Diabetes Surveillance System2003
- UKPDSIntensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) GroupLancet19983528378539742976
- PeyrotMRubinRRLauritzenTResistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) studyDiabetes Care2005282673267916249538
- CefaluWTOptimizing Glycemic Control. The search for feasible noninvasive insulin delivery systemsCanadian Journal of Diabetes2003274251
- ClementSStillJGKosuticGMcAllisterRGOral insulin product hexyl-insulin monoconjugate 2 (HIM2) in type 1 diabetes mellitus: the glucose stabilization effects of HIM2Diabetes Technol Ther2002445946612396740
- CefaluWTSkylerJSKouridesIAInhaled human insulin treatment in patients with type 2 diabetes mellitusAnn Intern Med200113420320711177333
- KeeganAWeak pulls the first pulmonary insulin, but uthers are in the worksDOC News200745
- KeeganAExit Exubera. Inhalable insulin is withdrawn due to weak salesDiabetes Forecast2007601918217270
- FunnellMMAndersonRMMSJAMA: the problem with compliance in diabetesJAMA2000284170911015809
- HayesRPBowmanLMonahanPOMarreroDGMcHorneyCAUnderstanding diabetes medications from the perspective of patients with type 2 diabetes: prerequisite to medication concordanceDiabetes Educ20063240441416772656
- TelserHZweifelPMeasuring willingness-to-pay for risk reduction: an application of conjoint analysisHealth Econ20021112913911921311
- LyndLDSandfordAJKellyEMReconcilable differences: a cross-sectional study of the relationship between socioeconomic status and the magnitude of short-acting beta-agonist use in asthmaChest20041261161116815486378
- MarraCALyndLDEsdaileJMKopecJAnisAHThe impact of low family income on self-reported health outcomes in patients with rheumatoid arthritis within a publicly funded health-care environmentRheumatology (Oxford)2004431390139715292531
- Sawtooth Software IncCBC/SSI Web6.4.2. edSequim, WASawtooth Software1999
- SAS Institute ISAS Statistical Software91 edCary, North CarolinaSAS Institute2004
- HanemannWWelfare evaluations in contingent valuation experimets with discrete responses: replyAmerican Journal of Agricultural Economics198469332341
- The 2nd DAWN International Summit5 November 2003L, UKA call to action to improve psychosocial care for people with diabetesPractical Diabetes International2003215
- VermeireEHearnshawHvan RoyenPDenekensJPatient adherence to treatment: three decades of research. A comprehensive reviewJ Clin Pharm Ther20012633134211679023
- DickinsonDWilkiePHarrisMTaking medicines: concordance is not complianceBMJ199931978710488029
- GarfieldSSmithFFrancisSAChalmersCCan patients’ preferences for involvement in decision-making regarding the use of medicines be predictedPatient Educ Couns20076636136717331691
- HauberABJohnsonFRSauriolLLescrauwaetBRisking health to avoid injections: preferences of Canadians with type 2 diabetesDiabetes Care2005282243224516123499
- AristidesMWestonARFitzGeraldPLe ReunCManiadakisNPatient preference and willingness-to-pay for Humalog Mix25 relative to Humulin 30/70: a multicountry application of a discrete choice experimentValue Health2004744245415449636
- SadriHMacKeiganLDLeiterLAEinarsonTRWillingness to pay for inhaled insulin: a contingent valuation approachPharmacoeconomics2005231215122716336016
- GuimarãesCA valuation of patients’ willingness-to-pay for insulin delivery in diabetesInternational Journal of Technology Assessment in Health Care20092518
- ChancellorJAballeaSLawrenceAPreferences of patients with diabetes mellitus for inhaled versus injectable insulin regimensPharmacoeconomics20082621723418282016
- PintoSLHoliday-GoodmanMBlackCDLeschDIdentifying factors that affect patients’ willingness to pay for inhaled insulinRes Soc Adm Pharm2009In press